HIV-1 drug resistance: can we overcome?
- 1 October 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 2 (7) , 751-761
- https://doi.org/10.1517/14712598.2.7.751
Abstract
Highly active antiretroviral therapy (HAART) targeting the viral reverse transcriptase and protease enzymes has advanced the treatment of HIV/AIDS. Nucleoside and non-nucleoside reverse transcriptase inhibitors and protease inhibitors used in combination can suppress viral replication thereby delaying disease progression. Emergence of HIV-1 mutated strains, resistant to one or more antiretroviral inhibitors or drug classes, remains one of the leading causes of treatment failure among patients living with HIV/AIDS. While advances in genotypic and phenotypic testing allow for drug resistance guided therapeutic management, the increasing prevalence of multi-drug resistance and an absence of new drug classes forewarn new problems in sustaining the effectiveness of HAART. One promising hope for continued benefit of antiretroviral therapy despite emergent resistance is the observed reduction in replicative ability or ‘fitness’ of multimutated viruses. This review discusses the development and influence of known drug mutations on drug susceptibility versus viral fitness.Keywords
This publication has 47 references indexed in Scilit:
- Broad Nucleoside‐Analogue Resistance Implications for Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase Mutations at Codons 44 and 118The Journal of Infectious Diseases, 2002
- Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to StavudineAntimicrobial Agents and Chemotherapy, 2001
- Phenotypic Drug Susceptibility Testing Predicts Long‐Term Virologic Suppression Better than Treatment History in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2001
- Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and SelectionJournal of Virology, 2000
- Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptaseDrug Resistance Updates, 2000
- Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotypeAIDS, 1999
- Mechanistic Studies Examining the Efficiency and Fidelity of DNA Synthesis by the 3TC-Resistant Mutant (184V) of HIV-1 Reverse TranscriptaseBiochemistry, 1999
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In VitroThe Journal of Infectious Diseases, 1999
- Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.Journal of Clinical Investigation, 1993